Prosensa: Recent Competitor Setbacks May Not Have Much Bearing On NDA Submission, Says Roth Capital
Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Prosensa Holding (NASDAQ:RNA) with a price target of $17, which represents a potential upside of 35% from where the stock is currently trading.
Chattopadhyay noted, “Recall that Prosensa has initiated a rolling NDA submission for drisapersen. Competitor Sarepta’s (NASDAQ:SRPT) setbacks with the agency are company specific, in our view. Given the urgency within the agency to approve a potentially disease stabilizing therapy, we continue to anticipate a positive panel vote in support of accelerated approval for drisapersen during mid-2015 and recommend owning Prosensa at current levels.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -11.7% and a 36.7% success rate. Chattopadhyay has a 34.0% average return when recommending RNA, and is ranked #3301 out of 3358 analysts.